ArticleScientific reports2025
Risk factors for pulmonary function alterations in children with metabolic dysfunction-associated fatty liver disease.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Intestinal neutral ceramidase exacerbates MASH pathogenesis.eGastroenterology · 2026Article
- Effects of metabolic syndrome on pulmonary infection in pediatric bronchial asthma: a narrative review.Frontiers in pediatrics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Children with metabolic dysfunction-associated fatty liver disease (MAFLD) may exhibit abnormal lung function. However, it is unclear whether these abnormalities are independent of BMI. Moreover, the specific patterns of abnormal pulmonary function parameters have not been fully characterized, and the risk factors associated with impaired pulmonary function remain insufficiently understood. This study included 40 overweight or obese children with MAFLD and 30 overweight or obese control subjects without MAFLD. Pulmonary function parameters and anthropometric parameters were compared between children with MAFLD and the control group. Additionally, liver function, lipid and glucose metabolism, and cytokine levels were assessed. Multivariable regression analysis was used to identify risk factors for abnormal pulmonary function in children with MAFLD. No significant difference in BMI was observed between the groups (p = 0.075). Pulmonary function tests showed that FVC was significantly higher in children with MAFLD compared to controls (p < 0.001). In contrast, PEF, FEV1/FVC, FEF50, FEF75, and MMEF were lower in the MAFLD group (p < 0.05). Multivariable regression analysis demonstrated that HOMA-IR was significantly and inversely associated with FEF25 (b = -1.51, 95% CI: -2.33 to -0.69, p = 0.001), FEF50 (b = -1.85, 95% CI: -3.01 to -0.70, p = 0.003), and FEF75 (b = -1.44, 95% CI: -2.53 to -0.35, p = 0.01) among children with MAFLD. Furthermore, IL-1β levels were negatively correlated with MMEF (b = -1.16, 95% CI: -2.17 to -0.149, p = 0.03) and FEF50 (b = -0.63, 95% CI: -1.16 to -0.09, p = 0.02). These findings indicate that children aged 8 to 14 years with MAFLD exhibit higher FVC, along with a lower FEV1/FVC ratio and impaired small airway function compared to controls. This impairment in lung function is independent of BMI. Furthermore, HOMA-IR values and elevated IL-1β levels are key risk factors linked to abnormal small airway function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.